

- 1: Solomon BL, Whitman T, Wood ME. Contribution of extended family history in assessment of risk for breast and colon cancer. *BMC Fam Pract.* 2016 Sep 1;17(1):126. doi: 10.1186/s12875-016-0521-0. PubMed PMID: 27580697; PubMed Central PMCID: PMC5007707.
- 2: Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. *Fam Cancer.* 2016 Jul 11. [Epub ahead of print] PubMed PMID: 27401692.
- 3: Wood ME. Family history matters. *Cancer.* 2016 Sep 1;122(17):2618-20. doi: 10.1002/cncr.30078. Epub 2016 Jun 3. PubMed PMID: 27258002.
- 4: Holmes CE, Levis JE, Schneider DJ, Bambace NM, Sharma D, Lal I, Wood ME, Muss HB. Platelet phenotype changes associated with breast cancer and its treatment. *Platelets.* 2016 May 2:1-9. [Epub ahead of print] PubMed PMID: 27135253.
- 5: Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, Tung NM, Manoukian S, Phelan CM, Sun P, Narod SA; Hereditary Breast Cancer Research Group. The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. *Br J Cancer.* 2016 May 10;114(10):1160-4. doi: 10.1038/bjc.2016.58. Epub 2016 Mar 17. PubMed PMID: 26986251; PubMed Central PMCID: PMC4865972.
- 6: Ji Y, Rounds T, Crocker A, Sussman B, Hovey RC, Kingsley F, Muss HB, Garber JE, Wood ME. The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. *Cancer Prev Res (Phila).* 2016 May;9(5):379-84. doi: 10.1158/1940-6207.CAPR-15-0300. Epub 2016 Feb 23. PubMed PMID: 26908565; PubMed Central PMCID: PMC4965880.
- 7: Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, Kotsopoulos J; Hereditary Breast Cancer Clinical Study Group. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. *Fertil Steril.* 2016 Mar;105(3):781-5. doi: 10.1016/j.fertnstert.2015.11.034. Epub 2015 Dec 14. PubMed PMID: 26698676.
- 8: Peshkin BN, Kelly S, Nusbaum RH, Similuk M, DeMarco TA, Hooker GW, Valdimarsdottir HB, Forman AD, Joines JR, Davis C, McCormick SR, McKinnon W, Graves KD, Isaacs C, Garber J, Wood M, Jandorf L, Schwartz MD. Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling. *J Genet Couns.* 2016 Jun;25(3):472-82. doi: 10.1007/s10897-015-9897-6. Epub 2015 Oct 12. PubMed PMID: 26455498; PubMed Central PMCID: PMC4829475.
- 9: Segev Y, Rosen B, Lubinski J, Gronwald J, Lynch HT, Moller P, Kim-Sing C, Ghadirian P, Karlan B, Eng C, Gilchrist D, Neuhausen SL, Eisen A, Friedman E, Euhus D, Ping S, Narod SA; Hereditary Breast Cancer Study Group. Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. *Fam Cancer.* 2015 Sep;14(3):383-91. doi: 10.1007/s10689-015-9798-8. PubMed PMID: 25838159; PubMed Central PMCID: PMC4962606.
- 10: Othman E, Wang J, Sprague BL, Rounds T, Ji Y, Herschorn SD, Wood ME. Comparison of false positive rates for screening breast magnetic resonance imaging (MRI) in high risk women performed on stacked versus alternating schedules. *Springerplus.* 2015 Feb 13;4:77. doi: 10.1186/s40064-015-0793-1.

eCollection 2015. PubMed PMID: 25741458; PubMed Central PMCID: PMC4340856.

11: Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Int J Cancer*. 2015 Sep 1;137(5):1136-46. doi: 10.1002/ijc.29386. Epub 2014 Dec 18. PubMed PMID: 25482078; PubMed Central PMCID: PMC4458227.

12: Vatovec C, Erten MZ, Kolodinsky J, Brown P, Wood M, James T, Sprague BL. Ductal carcinoma in situ: a brief review of treatment variation and impacts on patients and society. *Crit Rev Eukaryot Gene Expr*. 2014;24(4):281-6. Review. PubMed PMID: 25403959; PubMed Central PMCID: PMC4372113.

13: Butrick M, Kelly S, Peshkin BN, Luta G, Nusbaum R, Hooker GW, Graves K, Feeley L, Isaacs C, Valdimarsdottir HB, Jandorf L, DeMarco T, Wood M, McKinnon W, Garber J, McCormick SR, Schwartz MD. Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. *Genet Med*. 2015 Jun;17(6):467-75. doi: 10.1038/gim.2014.125. Epub 2014 Sep 18. PubMed PMID: 25232856; PubMed Central PMCID: PMC4364924.

14: Wood ME, Lu KH, Wollins DS, Hughes KS. Reply to A.S. Sie et al, K. Hemminki et al, and J. Larsen Haidle. *J Clin Oncol*. 2014 Oct 10;32(29):3346-7. doi: 10.1200/JCO.2014.56.8535. Epub 2014 Sep 2. PubMed PMID: 25185101.

15: Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21. PubMed PMID: 24951267; PubMed Central PMCID: PMC4131437.

16: Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB. A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. *BMC Cancer*. 2014 Jun 10;14:421. doi: 10.1186/1471-2407-14-421. PubMed PMID: 24915755; PubMed Central PMCID: PMC4059881.

17: Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. *Psychooncology*. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17. PubMed PMID: 24839250; PubMed Central PMCID: PMC4234699.

18: Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. *J Clin Oncol*. 2014 Mar 10;32(8):824-9. doi: 10.1200/JCO.2013.51.4661. Epub 2014 Feb 3. PubMed PMID: 24493722; PubMed Central PMCID: PMC4876350.

19: Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, Kohlmann W, Lindor NM,

Mulvey TM, Robinson L, Rubinstein WS, Stoffel EM, Snyder C, Syngal S, Merrill JK, Wollins DS, Hughes KS; American Society of Clinical Oncology. American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. *J Clin Oncol*. 2014 Mar 10;32(8):833-40. doi: 10.1200/JCO.2013.50.9257. Epub 2014 Feb 3. PubMed PMID: 24493721; PubMed Central PMCID: PMC3940540.

20: Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, Neuhausen SL, Karlan B, Kim-Sing C, Huzarski T, Gronwald J, McCuaig J, Senter L, Tung N, Ghadirian P, Eisen A, Gilchrist D, Blum JL, Zakalik D, Pal T, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. *Breast Cancer Res Treat*. 2014 Feb;143(3):579-86. doi: 10.1007/s10549-013-2823-4. Epub 2014 Jan 24. PubMed PMID: 24458845.

21: Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Kinney AY, Luta G, Kelleher S, Leventhal KG, Vegella P, Tong A, King L. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. *J Clin Oncol*. 2014 Mar 1;32(7):618-26. doi: 10.1200/JCO.2013.51.3226. Epub 2014 Jan 21. PubMed PMID: 24449235; PubMed Central PMCID: PMC3927731.

22: Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, Lian JB. Standardizing analysis of circulating microRNA: clinical and biological relevance. *J Cell Biochem*. 2014 May;115(5):805-11. doi: 10.1002/jcb.24745. PubMed PMID: 24357537; PubMed Central PMCID: PMC3992702.

23: Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachqui M, Chornokur G, Ping S, Narod SA; Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. *Br J Cancer*. 2014 Jan 21;110(2):530-4. doi: 10.1038/bjc.2013.741. Epub 2013 Nov 28. PubMed PMID: 24292448; PubMed Central PMCID: PMC3899769.

24: Valentini A, Lubinski J, Byrski T, Ghadirian P, Moller P, Lynch HT, Ainsworth P, Neuhausen SL, Weitzel J, Singer CF, Olopade OI, Saal H, Lyonnet DS, Foulkes WD, Kim-Sing C, Manoukian S, Zakalik D, Armel S, Senter L, Eng C, Grunfeld E, Chiarelli AM, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. *Breast Cancer Res Treat*. 2013 Nov;142(1):177-85. doi: 10.1007/s10549-013-2729-1. Epub 2013 Oct 18. PubMed PMID: 24136669; PubMed Central PMCID: PMC3940343.

25: Semple J, Metcalfe KA, Lynch HT, Kim-Sing C, Senter L, Pal T, Ainsworth P, Lubinski J, Tung N, Eng C, Gilchrist D, Blum J, Neuhausen SL, Singer CF, Ghadirian P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. *Ann Surg Oncol*. 2013 Nov;20(12):3817-22. doi: 10.1245/s10434-013-3040-4. Epub 2013 Jun 6. PubMed PMID: 23740344; PubMed Central PMCID: PMC4608025.

26: Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group. The incidence

of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. *Gynecol Oncol*. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3. PubMed PMID: 23562522.

27: Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. *Nat Rev Clin Oncol*. 2013 May;10(5):289-301. doi: 10.1038/nrclinonc.2013.41. Epub 2013 Mar 26. Review. PubMed PMID: 23529000.

28: Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, Neuhausen SL, Kim-Sing C, Tung N, Karlan B, Foulkes WD, Sun P, Narod S; Hereditary Breast Cancer Study Group. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. *Fertil Steril*. 2013 May;99(6):1724-8. doi: 10.1016/j.fertnstert.2013.01.109. Epub 2013 Feb 13. PubMed PMID: 23414920.

29: Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachaqui M, Ping S, Narod SA; Hereditary Breast Cancer Study Group. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer*. 2012 Dec 4;107(12):2005-9. doi: 10.1038/bjc.2012.483. Epub 2012 Oct 25. PubMed PMID: 23099806; PubMed Central PMCID: PMC3516682.

30: Senst N, Llacuachaqui M, Lubinski J, Lynch H, Armel S, Neuhausen S, Ghadirian P, Sun P, Narod SA; Hereditary Breast Cancer Study Group. Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation. *Clin Genet*. 2013 Jul;84(1):43-6. doi: 10.1111/cge.12037. Epub 2012 Nov 7. PubMed PMID: 23066998.

31: Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. *J Clin Oncol*. 2012 Oct 20;30(30):3734-45. doi: 10.1200/JCO.2012.41.8681. Epub 2012 Sep 24. Review. PubMed PMID: 23008293.

32: Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res*. 2012 Mar 9;14(2):R42. PubMed PMID: 22405187; PubMed Central PMCID: PMC3446376.

33: McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim-Sing C, Karlan B, Foulkes WD, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. *Obesity (Silver Spring)*. 2012 Jun;20(6):1288-92. doi: 10.1038/oby.2011.394. Epub 2012 Jan 19. PubMed PMID: 22262156.

34: Ligibel JA, Meyerhardt J, Pierce JP, Najita J, Shockro L, Campbell N, Newman VA, Barbier L, Hacker E, Wood M, Marshall J, Paskett E, Shapiro C. Impact of a telephone-based physical activity intervention upon exercise behaviors and fitness in cancer survivors enrolled in a cooperative group setting. *Breast Cancer Res Treat*. 2012 Feb;132(1):205-13. doi: 10.1007/s10549-011-1882-7. Epub 2011 Nov 24. PubMed PMID: 22113257; PubMed Central PMCID: PMC3353544.

35: Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, Foulkes WD, Kilar E, Kim-Sing C, Neuhausen SL, Armel S, Gilchrist D, Sweet K, Gronwald J, Eisen A, Gorski B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. *Int J Cancer*. 2012 Jul 1;131(1):229-34. doi: 10.1002/ijc.26369. Epub 2011 Sep 22. PubMed PMID: 21834074; PubMed Central PMCID: PMC3334396.

36: Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med*. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoal103507. Epub 2011 Jun 4. Erratum in: *N Engl J Med*. 2011 Oct 6;365(14):1361. PubMed PMID: 21639806.

37: Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. *Cancer*. 2011 May 1;117(9):1812-8. doi: 10.1002/cncr.25595. Epub 2010 Nov 10. PubMed PMID: 21509758; PubMed Central PMCID: PMC3413077.

38: Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. *Oncologist*. 2011;16(4):424-31. doi: 10.1634/theoncologist.2010-0435. Epub 2011 Mar 8. PubMed PMID: 21385795; PubMed Central PMCID: PMC3228118.

39: Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. *J Natl Cancer Inst*. 2010 Dec 15;102(24):1874-8. doi: 10.1093/jnci/djq443. Epub 2010 Nov 23. PubMed PMID: 21098759.

40: Wood ME, Fama TA, Ashikaga T, Muss HB. Discrepancy between preference and actual adjuvant therapy for breast cancer. *Clin Breast Cancer*. 2010 Oct 1;10(5):398-403. doi: 10.3816/CBC.2010.n.053. PubMed PMID: 20920985.

41: Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. BRCA1 and BRCA2 families and the risk of skin cancer. *Fam Cancer*. 2010 Dec;9(4):489-93. doi: 10.1007/s10689-010-9377-y. PubMed PMID: 20809262.

42: Flynn BS, Wood ME, Ashikaga T, Stockdale A, Dana GS, Naud S. Primary care physicians' use of family history for cancer risk assessment. *BMC Fam Pract*. 2010 Jun 3;11:45. doi: 10.1186/1471-2296-11-45. PubMed PMID: 20525302; PubMed Central PMCID: PMC2898682.

43: Vicus D, Finch A, Rosen B, Fan I, Bradley L, Cass I, Sun P, Karlan B, McLaughlin J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. *Gynecol Oncol*. 2010 Aug 1;118(2):155-9. doi: 10.1016/j.ygyno.2010.03.009. Epub 2010 May 10. PubMed PMID: 20452659.

- 44: Wood ME, Stanley MA, Crocker AM, Kingsley FS, Leiman G. Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection. *Acta Cytol.* 2009 Jul-Aug;53(4):410-5. PubMed PMID: 19697725.
- 45: McKinnon W, Banks KC, Skelly J, Kohlmann W, Bennett R, Shannon K, Larson-Haidle J, Ashakaga T, Weitzel JN, Wood M. Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals. *Fam Cancer.* 2009;8(4):363-9. doi: 10.1007/s10689-009-9248-6. Epub 2009 May 24. PubMed PMID: 19466581; PubMed Central PMCID: PMC3528358.
- 46: Ibarra-Drendall C, Wilke LG, Zalles C, Scott V, Archer LE, Lem S, Yee LD, Lester J, Kulkarni S, Murekeyisoni C, Wood M, Wilson K, Garber J, Gentry C, Stouder A, Broadwater G, Baker JC Jr, Vasilatos SN, Owens E, Rabiner S, Barron AC, Seewaldt VL. Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. *Cancer Epidemiol Biomarkers Prev.* 2009 May;18(5):1379-85. doi: 10.1158/1055-9965.EPI-08-1210. Epub 2009 Apr 21. PubMed PMID: 19383884; PubMed Central PMCID: PMC3640981.
- 47: Pal T, Keefe D, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Fertility in women with BRCA mutations: a case-control study. *Fertil Steril.* 2010 Apr;93(6):1805-8. doi: 10.1016/j.fertnstert.2008.12.052. Epub 2009 Feb 6. PubMed PMID: 19200971.
- 48: Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. *Support Care Cancer.* 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27. PubMed PMID: 19037667.
- 49: Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2008 Oct 1;100(19):1361-7. doi: 10.1093/jnci/djn313. Epub 2008 Sep 23. PubMed PMID: 18812548; PubMed Central PMCID: PMC2556701.
- 50: Wood ME, Stockdale A, Flynn BS. Interviews with primary care physicians regarding taking and interpreting the cancer family history. *Fam Pract.* 2008 Oct;25(5):334-40. doi: 10.1093/fampra/cmn053. Epub 2008 Sep 1. PubMed PMID: 18765407; PubMed Central PMCID: PMC2722235.
- 51: Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P; Hereditary Breast Cancer Study Group, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, Nedelcu R, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C. Rapid progression of prostate cancer in men with a BRCA2 mutation. *Br J Cancer.* 2008 Jul 22;99(2):371-4. doi: 10.1038/sj.bjc.6604453. Epub 2008 Jun 24. PubMed PMID: 18577985; PubMed Central PMCID: PMC2480973.

52: Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. *Breast Cancer Res Treat.* 2009 Mar;114(1):127-35. doi: 10.1007/s10549-008-9977-5. Epub 2008 May 16. PubMed PMID: 18483851; PubMed Central PMCID: PMC3033012.

53: McKinnon W, Naud S, Ashikaga T, Colletti R, Wood M. Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. *J Genet Couns.* 2007 Aug;16(4):433-56. Epub 2007 Jun 27. PubMed PMID: 17594133.

54: Burdette-Radoux S, Wood ME, Olin JJ, Laughlin RS, Crocker AM, Ashikaga T, Muss HB. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer. *Breast J.* 2007 May-Jun;13(3):274-80. PubMed PMID: 17461902.

55: Sprague J, Wood M. Breast cancer prevention: time for randomized controlled trials with statins. *Arch Intern Med.* 2006 May 22;166(10):1143-4; author reply 1144. PubMed PMID: 16717178.

56: Sprague JR, Wood ME. Statins and breast cancer prevention: time for randomized controlled trials. *J Clin Oncol.* 2006 May 1;24(13):2129-30; author reply 2130-1. PubMed PMID: 16648518.

57: Eneman JD, Wood ME, Muss HB. Selecting adjuvant endocrine therapy for breast cancer. *Oncology (Williston Park).* 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4. Review. PubMed PMID: 15700624.

58: Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. *Cancer.* 2003 Aug 1;98(3):597-602. Review. PubMed PMID: 12879478.